Search Results
Search for other papers by Daniela Dias in
Google Scholar
PubMed
Search for other papers by Inês Damásio in
Google Scholar
PubMed
Search for other papers by Pedro Marques in
Google Scholar
PubMed
Search for other papers by Helder Simões in
Google Scholar
PubMed
Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School: Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
developed for advanced thyroid carcinoma. Multikinase inhibitors have a non-negligible toxicity that may decrease the patient’s quality of life. Novel insights GEMOX (gemcitabine plus oxaliplatin) may have a role in patients with
Search for other papers by Carla Gambale in
Google Scholar
PubMed
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Search for other papers by Chiara Romei in
Google Scholar
PubMed
Search for other papers by Alessandro Celi in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
advanced/metastatic ( 1 ). According to European Medicines Agency (EMA) indications, two multikinase inhibitors (MKIs) (i.e. vandetanib and cabozantinib) and one highly selective RET inhibitor (i.e. selpercatinib) have been approved for the treatment of
Search for other papers by Elisa Minaldi in
Google Scholar
PubMed
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Search for other papers by Matilde Viglione in
Google Scholar
PubMed
Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
, interquartile range; MKI, multikinase inhibitors; TC, thyroid carcinoma. Sorafenib The group treated with sorafenib was represented by 74 patients, of which 40/74 (54.1%) were females and 34/74 (45.9%) were males. The mean age at the starting of
Search for other papers by Ana Piñar-Gutiérrez in
Google Scholar
PubMed
Search for other papers by Ana R Romero-Lluch in
Google Scholar
PubMed
Search for other papers by Suset Dueñas-Disotuar in
Google Scholar
PubMed
Search for other papers by Irene de Lara-Rodríguez in
Google Scholar
PubMed
Search for other papers by María Ángeles Gálvez-Moreno in
Google Scholar
PubMed
Search for other papers by Tomás Martín-Hernández in
Google Scholar
PubMed
Search for other papers by Jorge García-Alemán in
Google Scholar
PubMed
Search for other papers by Guillermo Martínez-de Pinillos in
Google Scholar
PubMed
Search for other papers by Elena Navarro-González in
Google Scholar
PubMed
/Hematology 2005 56 365 – 378 . ( https://doi.org/10.1016/j.critrevonc.2005.03.011 ) 9 Navarro-Gonzalez E . Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine-resistant differentiated thyroid
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed
Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Search for other papers by Noemi Giancola in
Google Scholar
PubMed
Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Gianfranco Parati in
Google Scholar
PubMed
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Introduction Multikinase inhibitors (MKIs) with strong anti-angiogenetic action are frequently used for the treatment of advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) or medullary thyroid cancers (MTCs) ( 1 , 2
Search for other papers by Grace Segall in
Google Scholar
PubMed
Search for other papers by Ravinder Singh in
Google Scholar
PubMed
Search for other papers by Min-Hua Jen in
Google Scholar
PubMed
Search for other papers by Isaac Sanderson in
Google Scholar
PubMed
Search for other papers by Alex Rider in
Google Scholar
PubMed
Search for other papers by Katie Lewis in
Google Scholar
PubMed
Search for other papers by Urpo Kiiskinen in
Google Scholar
PubMed
MTC for whom treatment with systemic therapy is planned ( 12 ). Systemic therapies in advanced or metastatic MTC (aMTC) include multikinase inhibitors (MKIs) and selective RET inhibitors ( 12 , 13 ). ESMO treatment guidelines from April 2022
Search for other papers by Andrew G Gianoukakis in
Google Scholar
PubMed
Search for other papers by Jennifer H Choe in
Google Scholar
PubMed
Search for other papers by Daniel W Bowles in
Google Scholar
PubMed
Search for other papers by Marcia S Brose in
Google Scholar
PubMed
Search for other papers by Lori J Wirth in
Google Scholar
PubMed
Search for other papers by Taofeek Owonikoko in
Google Scholar
PubMed
Search for other papers by Svetlana Babajanyan in
Google Scholar
PubMed
Search for other papers by Francis P Worden in
Google Scholar
PubMed
Gild ML Tsang VHM Clifton-Bligh RJ & Robinson BG . Multikinase inhibitors in thyroid cancer: timing of targeted therapy . Nature Reviews. Endocrinology 2021 17 225 – 234 . ( https://doi.org/10.1038/s41574-020-00465-y ) 10 Brose MS Smit
Search for other papers by Pepijn van Houten in
Google Scholar
PubMed
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
Search for other papers by James Nagarajah in
Google Scholar
PubMed
Search for other papers by Janneke E W Walraven in
Google Scholar
PubMed
Search for other papers by Martin Jaeger in
Google Scholar
PubMed
Search for other papers by Adriana C H van Engen-van Grunsven in
Google Scholar
PubMed
Search for other papers by Johannes W Smit in
Google Scholar
PubMed
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed
included RAI-refractory NMTC patients with different histological subtypes and genotypes, the multikinase inhibitor sorafenib did not reinduce RAI uptake in RAI-refractory NMTC patients ( 23 ). So, while there are some valid options for redifferentiation
Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan
Search for other papers by Haruhiko Yamazaki in
Google Scholar
PubMed
Search for other papers by Kiminori Sugino in
Google Scholar
PubMed
Search for other papers by Ryohei Katoh in
Google Scholar
PubMed
Search for other papers by Kenichi Matsuzu in
Google Scholar
PubMed
Search for other papers by Wataru Kitagawa in
Google Scholar
PubMed
Search for other papers by Mitsuji Nagahama in
Google Scholar
PubMed
Search for other papers by Aya Saito in
Google Scholar
PubMed
Search for other papers by Koichi Ito in
Google Scholar
PubMed
. Available from: https://www.nccn.org/home (accessed 18 March 2024)). Anti-angiogenic drugs are multikinase inhibitors, including sorafenib, lenvatinib, and cabozantinib. Targeted agents include selective RET inhibitors (selpercatinib or pralsetinib) for
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Junyu Tong in
Google Scholar
PubMed
Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
Search for other papers by Maomei Ruan in
Google Scholar
PubMed
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Search for other papers by Hao Fu in
Google Scholar
PubMed
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Search for other papers by Qiong Luo in
Google Scholar
PubMed
Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Zhiyan Liu in
Google Scholar
PubMed
Search for other papers by Zhongwei Lv in
Google Scholar
PubMed
Search for other papers by Libo Chen in
Google Scholar
PubMed
-refractory differentiated thyroid carcinoma may be helpful to discover the pathological basis of radioiodine-refractory differentiated thyroid carcinoma. What we should not ignore is that most multikinase inhibitors do not bring significant overall survival benefit but